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G protein-coupled receptors (GPCRs), which are modulated by a variety of endogenous and syn-
thetic ligands, represent the largest family of druggable targets in the human genome. Recent
structural and molecular studies have both transformed and expanded classical concepts of
receptor pharmacology and have begun to illuminate the distinct mechanisms by which structur-
ally, chemically, and functionally diverse ligands modulate GPCR function. These molecular
insights into ligand engagement and action have enabled new computational methods and
accelerated the discovery of novel ligands and tool compounds, especially for understudied
and orphan GPCRs. These advances promise to streamline the development of GPCR-targeted
medications.Introduction
G protein-coupled receptors (GPCRs) are seven-transmem-
brane integral membrane proteins that typically translate 
extracellular stimulation into intracellular signals. GPCR activa-
tion is usually mediated by agonist binding, which stabilizes 
receptor conformations that recruit and ultimately activate 
intracellular transducers. GPCR agonist ligands are physically 
and chemically diverse and can include: photons; ions (H+, 
Zn2+, Ca2+, etc.); odorants; tastants; vitamins (e.g., niacin, 
vitamin A1 aldehyde, etc.); peptidic and non-peptidergic hor-
mones (estrogen, angiotensin, etc.); proteins (e.g., chemo-
kines); neurotransmitters (dopamine, serotonin, etc.); natural 
products (morphine, salvinorin A, etc.); a large number of 
intermediary metabolites (ATP, ADP, fatty acids, bile acids, 
etc.); and products from human commensal bacteria (see 
Allen and Roth [2011] and Roth and Kroeze [2015] for reviews). 
Intracellularly, GPCR activation is translated into various 
signals mediated via heterotrimeric G proteins, arrestins (Lut-
trell et al., 1999), kinases (Benovic et al., 1989), ion channels, 
and various scaffolding proteins (Brown et al., 2003) (Figure 1). 
In this context, arrestins function to abrogate G protein-
mediated signaling (Lohse et al., 1990), as scaffolds for 
GPCR internalization via clathrin-coated vesicles (Goodman 
et al., 1996), and as scaffolds for signaling (Luttrell et al., 
1999) (Figure 1).
GPCRs, of which there are more than 800 in humans (Fredriks-
son et al., 2003), comprise the largest family of membrane pro-
teins in the human genome. Several classification schemes for 
GPCRs have been used, and in this Review, we will adhere to 
the current International Union of Pharmacology (IUPHAR) clas-
sification that includes five main families: Rhodopsin family 
(class A), Secretin family (class B), Glutamate family (class C), 
Frizzled/Taste family (class F), and Adhesion Family (see Alex-
ander et al. [2015] for details). In this Review, we highlight 
findings that demonstrate how insights into ligand interactionsat GPCRs are transforming molecular pharmacology and drug
discovery.
Importance of GPCRs for Physiology, Disease, and
Therapeutics
As of 2017, between 20%–30% of FDA-approved medications
target GPCRs (Rask-Andersen et al., 2011). The popularity of
GPCRs as drug targets is predominantly due to their physiolog-
ical relevance, as GPCRs are expressed in most of the body’s
tissues, are involved in cellular communication, and participate
in virtually all aspects of human physiology via GPCR-mediated
signal transduction, as well as their druggability, as GPCRs
possess binding pockets with beneficial physiochemical proper-
ties that lend to the design of drug-like small molecules (Mason
et al., 2012). Particularly prominent therapeutic applications
involving GPCRs (see Figure 2A) include opioid analgesics
(m opioid receptor; OPRM1 receptor agonists), antihistamines
(HRH1-histamine antagonists), anticholinergics (CHRM antago-
nists), typical and atypical antipsychotics (D2 dopamine receptor
antagonists; DRD2), antimigraine drugs (5-HT1D serotonergic
agonists; HTR1D), b2-agonists for asthma (ADBAR2), and anti-
hypertensives (targeting a1 adrenergic and angiotensin II recep-
tors; ADAR1, ATGR1).
In addition to being therapeutic targets for drug discovery,
GPCR variants are occasionally implicated in disease pro-
cesses. Indeed, dozens of monogenic diseases have been
linked to constitutively activating mutations (CAMs), which
augment GPCR constitutive activity. These include such condi-
tions as congenital stationary night blindness caused by
rhodopsin CAMs (McAlear et al., 2010), uveal melanoma by
CAMs of the cysteinyl leukotriene receptor 2 (Moore et al.,
2016), and many others (Smit et al., 2007). Additionally, loss-
of-function GPCR mutations are occasionally linked to human
disease. V2-vasopressin receptor mutations, for example, are
associated with nephrogenic diabetes insipidus (Pan et al.,
Figure 1. Different Ligand-Stabilized GPCR
Conformations Cause Binding and Activa-
tion of Distinct Signal Transducers, in-
cluding G Proteins and Arrestins
Left: crystal structure of b2AR (light blue cartoon)
coupled to Gas (blue), Gb (orange), Gg (green)
heterotrimer (PDB: 3SN6 [Rasmussen et al.,
2011b]) illustrates G protein-mediated signaling.
Upon heterotrimer activation, subunits dissociate,
and Ga modulates second messenger production
such as cAMP production through Gas-mediated
activation of adenylyl cyclase. Gbg modulates
separate Ga-independent downstream signaling
networks such as ion channels, phospholipases,
and receptor kinases. Right: crystal structure of
rhodopsin (light blue cartoon) coupled to b-arrestin
(salmon) (PDB: 4ZWJ [Kang et al., 2015]) illus-
trates arrestin-mediated effects such as receptor
internalization or activation of kinase signaling
networks.1992), and drugs which rescue the misfolded phenotype of
V2-vasopressin receptor mutants via action as pharmacological
chaperones have been proposed as therapeutics (Morello
et al., 2000).
GPCRs as Deleterious Off-Targets in Therapeutic Drug
Discovery
GPCRs are also frequent medication ‘‘off-targets’’ that display
unpredicted interactions, which can result in unanticipated
therapeutic (Roth et al., 2004) or life-threatening side effects
(Rothman et al., 2000). The most infamous example is likely the
anti-obesity drug fenfluramine, which was withdrawn because
of association with valvular heart disease in many individuals
(Allen and Roth, 2011; Roth, 2007). Years after fenfluramine’s
widely publicized withdrawal from the world-wide market and
legal damages totaling more than $10 billion, it was discovered
that the compound’s metabolite—norfenfluramine—activated
cardiac 5-HT2B serotonin receptors, leading eventually to
valvular heart disease (Rothman et al., 2000; Roth, 2007). Since
then, several more drugs have been withdrawn due to similar
5-HT2B-mediated valvular heart disease complications (Roth,
2007; Allen and Roth, 2011).
As GPCRs represent frequent off-targets for drugs that target
kinases and other non-GPCRmolecular targets, compounds are
typically profiled against large numbers of clonedGPCRs prior to
clinical trials in humans (Allen and Roth, 2011). Importantly, the
potent actions of sorafinib and many other approved and inves-
tigational kinase inhibitors on serotonergic, purinergic, and other
GPCRs have been discovered via GPCR profiling (Elkins et al.,
2016). Identification of potentially important off-target actions
of drugs through GPCRs is also facilitated by large databases
of drug-target information, including ChEMBL (https://www.
ebi.ac.uk/chembl/), PubChem (https://pubchem.ncbi.nlm.nih.
gov/), PHAROS (https://pharos.nih.gov/idg/index), and the Ki
Database (https://kidbdev.med.unc.edu/databases/kidb.php).
These cheminformatic datasets also have been useful for thein silico prediction and in vitro and in vivo confirmation of GPCRs
as relevant and important drug off-targets (Keiser et al., 2009).
Understudied and Orphan GPCRs and Their Therapeutic
Potential
Although there aremore than 350GPCR-targeted FDA approved
drugs, they target only a small sector of the universe of poten-
tially druggable GPCRs (Roth and Kroeze, 2015; Rask-Andersen
et al., 2011) (Figure 2A). Approximately 100 human GPCRs are
currently active targets for late-stage preclinical development,
and a total of nearly 400 small molecules are being actively inves-
tigated as therapeutics (Lafferty-Whyte et al., 2017). Current
drug development, though, is geared mainly toward those
GPCRs with extensive validation as potential therapeutic targets
(Lafferty-Whyte et al., 2017). Conversely, only a few orphan or
understudied GPCRs, ‘‘oGPCRs’’—as defined by (1) their
comparatively low number of publications, (2) their low number
of annotated small molecules interactors, or (3) absence of their
known endogenous ligands (Roth and Kroeze, 2015)—are
currently being investigated for therapeutic drug discovery.
Significantly, the Adhesion, Tastant, and Frizzled families of re-
ceptors are reported to have no annotated small drug-like mole-
cules in clinical testing (Lafferty-Whyte et al., 2017).
The lack of drug development programs targeting oGPCRs
stems mainly from risk aversion, as little is known regarding
oGPCR’s physiological roles and druggability. Although
knockout studies and replacement with chemogenetic mutant
GPCRs, such as DREADDs (designer receptors exclusively acti-
vated by designer drugs) (Roth, 2016), or chimeric opsins for
optogenetic studies, such as OptoXRs (Airan et al., 2009), repre-
sent strategies to identify the basic physiological roles of
oGPCRs, the biggest bottleneck remains the lack of chemical
tool compounds to reliably characterize receptor function
in vitro and in vivo. Yet, oGPCRs have emerged as important re-
ceptors for natural products and synthetic drugs; drugs targeting
oGPCRs have been used as tools to illuminate fundamental
Figure 2. GPCRome-wide Targets of
Approved and Marketed Medications and
How Ligands Uncover Unknown GPCR Phys-
iology toward Potential Therapeutic Applica-
tions
(A) Sphere size corresponds to number of approved
drugs for highlighted therapeutic GPCR target with
antagonists, agonists, and negative allosteric mod-
ulators shown in red, green, and blue, respectively.
Phylogenetic tree of the GPCRome highlights the
small fraction of GPCRs that are currently targeted
by approved medications.
(B) Representative examples and their structures are
shown for compounds used to identify previously
unknown pharmacology at various receptors.
Phylogenetic tree of the GPCRome highlights the
diversity of GPCRs identified as off-targets.
biological processes and therapeutic approaches mediated by
oGPCRs (Figure 2B). For instance, the naturally occurring
teratogen cyclopamine (Cooper et al., 1998) facilitated identifica-
tion of the smoothened receptor (SMO) as a hedgehog signaling
pathway modulator and target for cancer chemotherapy (Rudin
et al., 2009). Similarly, the discovery that the hallucinogen salvi-
norin A from the sage Salvia divinorum is a selective k-opioid
receptor agonist validated this receptor as a target for psychoto-
mimetic compounds (Roth et al., 2002). Several benzodiaze-
pines were found to also activate GPR68, suggesting that
some of the side effects of these anti-anxiety medications could
be mediated by this receptor (Huang et al., 2015b). Additionally,
the discovery of amphetamine actions at the TAAR1 trace amine
receptor (Bunzow et al., 2001) identified TAAR1 as a potential
target for neuropsychiatric diseases. The endogenous TAAR1
agonists known as thyronamines (Scanlan et al., 2004) revealed
trace amine receptors as potential mediators of metabolic, ther-
mogenic, and neurologic processes. Clearly, expanding our
understanding of GPCR on- and off-target pharmacology is
important for both successful drug discovery, as well as for illu-
minating basic biological and chemical processes in health and
disease. As exemplified by oGPCRs, however, we are still far
from a comprehensive molecular and physiological understand-
ing of GPCR biology.
Next, we review how recent molecular insights from crystal
structures have transformed classical receptor pharmacology
and facilitated our understanding of the mechanisms by which li-
gandsmodulate GPCR function. We further highlight the utility of
ligands in identifying and characterizing the physiological roles of
poorly understood GPCRs, and we provide an overview of cur-
rent advances to computationally leverage molecular insight
toward identifying novel GPCR ligands.
Toward a Structure-Based Understanding of
GPCR-Ligand Pharmacology
Key Pharmacological Concepts
Historically, the concepts of agonism and antagonism arose
from the observations of drug actions on isolated organs. One
example is highlighted by the ordered and regular agonist activ-
ity of acetylcholine, which is antagonized by atropine (Clark,
1926). Observations like these led to the initial concepts that
agonists either induce or stabilize an ‘‘active’’ state of a ‘‘recep-
tor,’’ while antagonists have no effect on their own but block
agonist access to this receptor. Once GPCRs were cloned and
expressed in vitro, it was observed that GPCRs also possessed
variable degrees of basal or constitutive activity and could popu-
late active signaling states in the absence of ligands. With a few
notable exceptions (e.g., adhesion-, thrombin-, and some viral
receptors, like the KHSV-related receptor), GPCRs typically
require exogenous agonists to stabilize fully active states for
maximal signaling. Endogenous agonists such as neurotransmit-
ters or hormones usually, but not invariably, maximally activate
their cognate GPCRs and are considered full agonists (see
Box 1); agonists which do not induce 100% activation are
defined as partial agonists. It is important to note that partial
agonists can appear as full agonists when receptor reserve is
present and that a full response of the system can be elicited,
even when not all receptors are occupied. Antagonists, on theother hand, are compounds (either naturally occurring or syn-
thetic) that block agonists activity; antagonists are classified as
inverse agonists (antagonists that decrease constitutive activity)
or neutral antagonists (antagonists that inhibit agonist effects but
do not interfere with constitutive activity; Box 1, for further details
and see Roth [2016]).
Agonists, partial agonists, and antagonists interact with the
so-called orthosteric site, which represents the binding site
through which endogenous agonists activate the GPCR. Some
GPCRs, most notably the adhesion- (Hamann et al., 2015) and
protease-activated receptors (Coughlin, 2000), lack classical
endogenous agonists, although following proteolysis, an N-ter-
minal fragment occupies the orthosteric site.
Additionally, GPCRs may also be modulated allosterically by
molecules that bind at a site that is distinct from the orthosteric
site. Generally, allosteric modulators are classified as negative
allosteric modulators or positive allosteric modulators (NAMs
and PAMs, respectively) (Christopoulos et al., 2014) (Box 1). Allo-
steric modulators do not directly interact with the orthosteric site
but modulate the function of orthosteric ligands in a negative
(NAM) or positive (PAM) way. Molecules that interact with both
the orthosteric and allosteric sites are defined as bitopic ligands
and may be either agonists or antagonists. Allosteric modulators
can be endogenous, as in the case of the nearly universal allo-
steric modulators sodium (which is a NAM [Fenalti et al., 2014])
and cholesterol (which could function as a NAM or PAM [Katritch
et al., 2013]), or exogenous natural products or synthetic com-
pounds (Kenakin and Boselli, 1989).
GPCR ligands also often display functional selectivity or
biased signaling (Box 1; [Urban et al., 2007]), a process by which
ligands will direct or bias the signaling toward one pathway or
another (Figure 1). Related to this, although GPCRs were initially
classified based on the presumedmainG protein with which they
interact (e.g., Gs-, Gi-, Gq-, and G12/13-coupled [Simon et al.,
1991]), the schema was abandoned due to observations that
GPCRs can couple to multiple G proteins (Asano et al., 1984).
Many theoretical models have arisen to explain the agonist,
allosteric, and antagonist actions and biased signaling, including
the highly useful, albeit phenomenological, operational model
(Box 1) of Black and Leff (1983). These simplified models
continue to be useful for quantifying and predicting drug actions
at GPCRs (Kenakin et al., 2012). With the discovery that GPCRs
require G proteins for activation, more detailed models have
arisen, including the so-called ternary (De Lean et al., 1980)
and extended ternary complex models (Samama et al., 1993),
as well as other models incorporating arrestin signaling (Roth,
2016) (Figure 3). The simple ternary and extended ternary com-
plex models are called ‘‘ternary’’ because they have three mem-
bers: receptor (R), ligand (L), and heterotrimeric G protein (G).
Extended versions incorporating other effectors, like arrestins
(Figure 3), are becoming validated by more mechanistic ap-
proaches which incorporate structure-based insights into ligand
pharmacology.
From a conceptual perspective, the ternary (De Lean et al.,
1980) and extended (Samama et al., 1993) complex models
were important because they predicted that GPCRs will
spontaneously adapt multiple active (R*1, R*2.) and inactive
(R0, R00, etc.) conformations. As also predicted, these transient
Box 1. Key Pharmacologic Concepts
CONSTITUTIVE ACTIVITY
Receptor-mediated signaling in the absence of ligand due to sponta-
neous population of active receptor states
FULL AGONISTS
Ligands that elicit maximum signal at the interrogated pathway (endog-
enous ligands are, per definition full agonists),
PARTIAL AGONISTS
Ligands that elicit activity below maximum level
INVERSE AGONISTS
Ligands that inhibit constitutive receptor activity
NEUTRAL ANTAGONISTS
Ligands that bind the receptor but do not affect constitutive receptor
activity
RECEPTOR RESERVE
Receptors not coupled to the system resulting in maximum signal by
activation of only a fraction of total receptors
ORTHOSTERIC SITE
Binding pocket accommodating endogenous receptor ligand
ALLOSTERIC SITE
Pocket distinct from the orthosteric site that can modulate ligand bind-
ing and receptor activity
PAMS AND NAMS
PAMs increase and NAMs decrease a receptor’s activity in response to




Ligands that possess both orthosteric and allosteric moieties
FUNCTIONAL SELECTIVITY/BIASED SIGNALING
Ability of ligands to impart different degrees of activation in distinct
pathways downstream of the receptor
OPERATIONAL MODEL
Mathematical description of receptor activation to quantify and predict
drug actionstates can spontaneously interact with G protein or arrestin
transducers to yield signaling complexes in the absence of
agonist (R*E with E = G protein, Arrestin, or other transducers)
(Figure 3). Indeed, this constitutive activity has been amply docu-
mented in both recombinant (Burns et al., 1997) and endogenous
(Arvanitakis et al., 1997) expression systems. These models also
predict that antagonists do not simply ‘‘antagonize’’ GPCRs, but
that they stabilize inactive states (R0L) and thereby inhibit consti-
tutive activity by acting as inverse agonists. The models further
predict that so-called neutral antagonists are likely to be rare,
as any ligand will bias the ensemble of spontaneously arising
conformations at least to some extent. The predictions that
antagonists are actually inverse agonists have been extensively
validated in recombinant systems in vitro (Chidiac et al., 1994)
and in vivo (Dillon et al., 2011). These models also predict that
the active states stabilized by agonist (R*L) might differ confor-
mationally from ternary signaling complexes (R*GL; R*AL). These
predictions have been validated by biochemical studies demon-
strating that G protein binding allosterically enhances agonist
binding affinity (Cerione et al., 1984).
The Impact of Molecular Insights into GPCR-Ligand
Interactions Illuminate Both Empirically Based and
Classical Concepts of Receptor Pharmacology
Historically, most of the initial functional concepts describing
binding interactions were based on phenomenological observa-
tions from ligand-binding and signaling studies done in recombi-
nant or endogenous systems. It wasn’t until technological
advances enabled the study of ligand-receptor interactions by
X-ray crystallography, NMR, and other biophysical assays that
high-resolution insights enabled the molecular characterization
of these distinct states (Figure 3). Initial biochemical studies sug-
gested that GPCR activation involves helical movements (Far-
rens et al., 1996); since then, crystallographic and now cryoelec-
tron microscopy (cryo-EM) structures are greatly enhancing our
understanding of the molecular characteristics that define
distinct GPCR conformations and signaling states. Most GPCRs
have been crystallized in apparently inactive conformations
(R0L), bound to antagonists or agonists (Tesmer, 2016). These
inactive-state structures highlight distinct features of inactive
GPCRs, such as binding of the endogenous NAM sodium
(Fenalti et al., 2014; Liu et al., 2012b) and the closed ‘‘ionic
Figure 3. Molecular and Structural Pharma-
cology Extend the Ternary Complex Model
for Quantitative Description of Drug Action
at GPCRs
Several ligand-bound inactive receptor states (R0L,
R00L, etc.) and ligand-bound active receptor states
(R*1L, R*2L, etc.), as well as ternary complex
structures of ligand- and effector-bound active
receptor states (R*GL, R*AL) (PDB: 3SN6 [Ras-
mussen et al., 2011b]; PDB: 4ZWJ [Kang et al.,
2015]), have been structurally characterized by
X-ray crystallography. Distinct conformational
characteristics such as the sodium-binding site of
the A2AAR (PDB: 4EIY [Liu et al., 2012b]), the ionic
lock of a nanobody stabilized b2AR (PDB: 5JQH
[Staus et al., 2016]), the PIF motif of the 5-HT2B
receptor (PDB: 4IB4 [Wacker et al., 2013], PDB:
3NY8 [Wacker et al., 2010]), and theNPxxYmotif of
a nanobody-bound b2AR (PDB: 3NY8 [Wacker
et al., 2010], PDB: 3P0G [Rasmussen et al., 2011a])
highlight diverse GPCR activation states.lock’’ (Staus et al., 2016). Intermediate active states in the
absence of bound effector (R*L) have been described for the
5-HT1B serotonin (Wang et al., 2013), the A2A adenosine (A2AAR)
(Allen et al., 2011), and neurotensin (White et al., 2012) receptors.
Structures of the5-HT2B serotonin receptor bound to the agonists
ergotamine (Wacker et al., 2013) and lysergic acid diethylamide
(LSD) (Wacker et al., 2017) have identified features of an
arrestin-biased intermediate state (R*L). They particularly include
‘‘active-like’’ conformations of selected ‘‘trigger’’ motifs, includ-
ing the ‘‘PIF’’ and ‘‘NpxxY’’ motifs (Figure 3; see Venkatakrishnan
et al. [2013] andWacker et al. [2017] for details), which are struc-
tural elements found in many GPCRs that are critical for receptor
activation. Active-state receptor structures stabilized by nano-
bodies have been particularly helpful in characterizing structural
hallmarks of GPCR activation (Huang et al., 2015a; Kruse et al.,
2013; Rasmussen et al., 2011a). Crystal structures have alsobeen determined for ternary signaling
complexes, such as that of b2AR with
agonist and hetereotrimeric G protein
(R*GL) (Rasmussen et al., 2011b) and
rhodopsin with arrestin (R*AL) (Kang
et al., 2015) (Figure 3). Recent cryo-EM
structures of R*GL states (Liang et al.,
2017; Zhang et al., 2017) have confirmed
some of the key features of the b2AR-G
protein complex. Finally, although not
associated with a high-resolution struc-
ture, a recent report indicates that under
some circumstances, a ‘‘megaplex’’ of
GPCR, heterotrimeric G protein, and ar-
restin may exist as a functioning signaling
entity (Thomsen et al., 2016), mediating
endosomally based GPCR signaling.
Thus, several conformational ensembles
predicted by these models have finally
been revealed structurally and greatly
improve our molecular understanding of
GPCR activation and regulation.As predicted by extended versions of the ternary complex
model (Roth, 2016; Samama et al., 1993) and verified bio-
physically (Manglik et al., 2015), multiple additional conforma-
tional intermediates exist. These include an R0L ‘‘ground-state,’’
which resembles inactive rhodopsin by maintaining an intact
ionic lock (Palczewski et al., 2000) between conserved residues
in TM III (typically an Arg) and TM VI (typically acidic like Asp or
Glu). Additionally, there are likely to be many intermediate states
between the active (R*L) and coupled (R*GL; R*AL) (Manglik
et al., 2015) receptor. Also, these extended models predict that
holo-GPCR complexes in the inactive (R0) and active (R*) states
exist; again, there is emerging biophysical evidence for these
conformational intermediates (Manglik et al., 2015). Finally,
these models predict that GPCRs and G proteins could exist in
a precoupled active-like state (R*G); although such states have
not yet been observed by direct structural studies, there is
Figure 4. Crystal Structures of Different GPCR-Ligand Complexes Highlight the Diverse Locations of Ligand-Binding Sites
Ligands are shown as stick models with transparent surfaces, and receptors are shown in cartoon representation in light blue. Complexes show retinal-bound
RHO, LY2119620-bound CHRM2, sodium-bound ADORA2A, ergotamine-bound HTR2B, CCR2-RA-[R]-bound CCR2, MK-0893-bound GCGR, CP-376395-
bound CRHR1, and BPTU-bound P2RY1.evidence for GPCR-G protein precoupling (RG; [Nobles et al., 
2005]). From the previously discussed observations, it is clear 
that multiple intermediate conformational states exist for GPCRs 
(alone and in complex with their effectors); elucidating the full 
complement of these effectors will be important for future efforts 
to design drugs to stabilize unique conformations and signaling 
intermediates.
Multiple Modes of Ligand Recognition: Orthosteric, 
Bitopic, and Allosteric GPCR-Ligand Interactions 
Although a plethora of previous structure-function studies iden-
tified residues critical for binding and activation of many GPCRs, 
the molecular details of ligand-GPCR interactions remained 
speculative until the first crystal structure of a GPCR, rhodopsin 
(Palczewski et al., 2000), provided the initial insight. Only a few 
GPCRs have been crystalized when bound to their endogenous 
ligands: rhodopsin and other opsins in complex with retinal 
(Palczewski et al., 2000) (Figure 4), glutamate in complex withthe extracellular domains of the mGluRs (Kunishima et al.,
2000), the adenosine-bound A2AAR (Lebon et al., 2011), the neu-
rotensin-bound NT-1 neurotensin receptor (White et al., 2012),
the endothelin-bound endothelin ETB receptor (Shihoya et al.,
2016), and adrenaline-bound b2AR (Ring et al., 2013). Since
rhodopsin is an exception, as it is covalently bound to its endog-
enous ligand, the first structural evidence for a more general
orthosteric binding site shared among many class A GPCRs
came from the structures of A2AAR and b2AR bound to their
diffusible endogenous ligands (Lebon et al., 2011; Ring et al.,
2013). For peptidergic GPCRs—based on structures of NT-1
neurotensin receptor in complex with neurotensin and the
d-opioid receptor in complex with a modified peptide agonist—
the orthosteric site likely overlaps with the shared class A orthos-
teric site and extends to include extensive contacts with the
extracellular loops. Recent cryo-EM studies showed that endog-
enous peptides of several class B receptors occupy a similar
orthosteric site as in class A receptors but appear to prefer an
even larger and more extended binding pocket (Liang et al.,
2017; Zhang et al., 2017).
Frequently, the orthosteric binding site of class A GPCRs re-
sides in the middle of the seven-transmembrane helical bundle,
located between the extracellular loops and the middle plane of
the membrane. Orthosteric sites exhibit different shapes and
chemostatic makeup depending on the nature of ligand. For
instance, more lipophilic ligands, such as cannabinoids, likely
enter the receptor from the membrane, and the hydrophobic
binding site is thus covered with residues from the extracellular
loops to provide a barrier to the hydrophilic extracellular space
(Hua et al., 2016). Conversely, peptide ligands—particularly for
class B receptors—are often large and possess considerable
flexibility (O’Connor et al., 2015) and require an orthosteric site
open to the extracellular space (Liang et al., 2017; Zhang et al.,
2017). Interestingly, while the nature of orthosteric sites is critical
to accommodate the ligands’ chemostatic and steric properties,
entry to the binding site through a network of receptor-specific
residues can present the largest energetic barrier to compound
binding (Dror et al., 2011). This finding is particularly important
for the design of receptor selective ligands and the control of re-
ceptor binding and dissociation rates.
Several studies have also provided critical structural insights
into ligand-binding sites that are structurally distinct from the or-
thosteric pocket as observed in class A GPCRs (Figure 4). These
include the M2 muscarinic receptor bound to a PAM located in a
vestibule above the orthosteric agonist binding site (Kruse et al.,
2013) and the corticotropin-releasing factor 1 receptor bound to
a presumed allosteric antagonist situated deep within the cyto-
plasmic portion of the helical bundle (Hollenstein et al., 2013).
Allosteric ligands have also been found bound to the putative
intracellular binding site of the C-terminal tail of the Ga subunit
in the chemokine receptors CCR9 (Oswald et al., 2016), and ex-
tra-helical binding sites in the glucagon (Jazayeri et al., 2016) and
purinergic P2Y1 receptor (Zhang et al., 2015) (Figure 4). Lastly,
general allosteric modulators of GPCR function include choles-
terol, which binds to different extra-helical binding sites in
different receptors (Gimpl, 2016), and sodium, which is bound
in a highly conserved pocket in the center of the helical bundle
below the orthosteric site (Katritch et al., 2014) (Figure 4).
Surprisingly, and despite decades of work exploring GPCR
allosteric modulation (Kenakin and Boselli, 1989; Lanzafame
et al., 1997), currently approved drugs mainly target orthosteric
sites (Figure 2A). Only a handful of FDA-approved GPCR allo-
steric modulators exist: cinacalcet, a NAM for the Calcium-
sensing receptor (CASR); maraviroc, a CCR5 chemokine recep-
tor NAM (CCR5); and the Smoothened receptor (SMO) NAMs
sonedigib and vismodegib. Despite these limited numbers,
targeting GPCRs allosterically remains a promising approach
for therapeutic drug development (Changeux andChristopoulos,
2016), as allosteric modulators are often more selective for
their targets, and allosterically modulating the actions of endog-
enous ligands provides substantial therapeutic benefits (Aitken
et al., 2009).
One important reason for the lack of allosteric therapeutics
could be that it is challenging to design compounds with suffi-
cient efficacy, as for most GPCRs, only the orthosteric pockethas evolved to govern receptor modulation. It is important to
note that, while endogenous ions, lipids, adaptor proteins, and
effectors modulate GPCR function (van der Westhuizen et al.,
2015), their interacting surfaces rarely possess the physiochem-
ical properties necessary for the structure-informed design of
syntheticmodulators. Other reasons for the lack of available allo-
steric modulators may include the lack of tool compounds, as
well as difficulties associated with developing suitable assays
to test for allosteric modulation. The increasing abundance of
crystal structures in combination with computational methods
should greatly facilitate the identification and characterization
of potential allosteric sites and patches, which in turn could
greatly accelerate the targeted design of allosteric modulators.
Biased Signaling and Kinetics as Drivers of
Ligand-Encoded Activities
GPCR signaling has both contextual and kinetic aspects,
and these can be exploited—ultimately, from structural ap-
proaches—to fine tune signaling for basic science and therapeu-
tic applications. As classically illustrated for b2AR, G protein
signaling generally occurs rapidly within a second or so of
agonist administration, while it typically lasts only a few minutes.
Signal termination occurs via desensitization through receptor
phosphorylation, arrestin binding, and internalization (Lefkowitz
and Shenoy, 2005). By contrast, arrestin binding and G pro-
tein-independent arrestinergic signaling events, such asMAP ki-
nase activation, typically occur on the minute to hour timescale
(Lefkowitz and Shenoy, 2005). The delineation of these two
signaling pathways has led to a major reconceptualization of
how GPCRs mediate their actions in both normal physiology
and disease and has ushered in a new era of GPCR drug discov-
ery to identify agonists biased for either G protein (White et al.,
2015) or arrestin (Allen et al., 2011) signaling with the promise
of improved therapeutic properties and reduced side effects
(DeWire and Violin, 2011). It should be noted, however, that iden-
tification and characterization of GPCR effectors remains an
active area of investigation (Paek et al., 2017) and that there
are likely many more unidentified intracellular proteins that
interact with signaling complexes and modulate GPCR signaling
(Paek et al., 2017).
From a mechanistic perspective, it remains largely unclear
how receptors mediate biased signaling, although recent struc-
tures and biophysical studies have begun to clarify this issue. For
instance, the structure of the arrestin-biased drug ergotamine
bound 5-HT2B serotonin receptor (Wacker et al., 2013) revealed
how ergotamine stabilizes a distinct receptor conformation in
which motifs that are essential for arrestin-biased signaling
(e.g., NPxxY) are activated, while others associated with G pro-
tein signaling (e.g., DRY or PIF) remain in the inactive state. NMR
(Liu et al., 2012a) and fluorescent spectroscopy studies (Rahmeh
et al., 2012) highlight how ligands selectively engage distinct mo-
tifs to stabilize GPCR conformations that are more conducive to
accommodating one effector over the other.
GPCR conformations associated with signal transduction
along specific pathways have further been shown to depend
on ligand-binding rates. In recent studies of LSD’s interactions
with 5-HT2B and 5-HT2A serotonin receptors, slow ligand kinetics
were found to be pivotal for arrestinergic signaling (Wacker et al.,
2017). Studies with D2 dopamine receptor further revealed how
kinetics modulate patterns of biased signaling (Klein Herenbrink 
et al., 2016). Taken together, these findings highlight a crucial 
kinetic component to functional selectivity at the level of com-
pound association, stabilization of distinct receptor conforma-
tions, and intracellular signal progression, which, together, 
appear to dramatically influence cellular responses.
The development and identification of drugs with differential 
patterns of biased signaling represent major areas of investiga-
tion, as these chemical tools help to delineate the downstream 
signaling network of GPCRs and are particularly useful to explore 
the physiological role of oGPCRs. Thus for instance, the halluci-
nogen LSD (Wacker et al., 2017) appears to display bias toward 
b-arrestin signaling (Box 1, Figure 1), while the synthetic opioids 
TRV-130 (DeWire et al., 2013) and PZM-21 (Manglik et al., 2016) 
are biased toward G protein signaling (Box 1, Figure 1). Allosteric 
modulators have also manifested biased potentiation in in-
stances in which a single GPCR may interact with multiple G pro-
teins, as in the case of the proton-sensing GPCR GPR68 (Huang 
et al., 2015b). Due to the differential expression of key signal 
transducers, signal transduction—and thus, signaling bias—
will vary between cell types (Urs et al., 2016). Exploiting signaling 
bias for drug discovery promises to yield much-improved com-
pounds that specifically target therapeutic pathways while 
avoiding pathologic events downstream of the same receptor 
(Allen et al., 2011; Violin and Lefkowitz, 2007).
Exploiting GPCR-Ligand Structures for Drug Discovery 
With the increasing number of GPCR structures, we can antici-
pate the generation of new chemical tools for the study of 
GPCRs by providing platforms for the structure-guided design 
of improved therapeutics. Since GPCRs are routinely crystallized 
in complex with ligands, structure-guided drug design is a prom-
ising alternative to classical methods of ligand discovery, which 
employ cycles of medicinal chemistry-based modification of ex-
isting scaffolds. However, although true structure-guided drug 
discovery and optimization have been routinely done for protein 
kinase inhibitors for more than a decade (Noble et al., 2004), the 
successful examples for GPCRs are rare. For example, struc-
ture-based drug design for A2AAR yielded new 1,2,4-triazine de-
rivatives that were shown cystallographically to adopt novel 
binding modes (Congreve et al., 2012). Similarly, new mGluR5 
metabotropic glutamate receptor NAMs were initially discovered 
via a combination of fragment-based screening and medicinal 
chemistry, and their binding modes subsequently were identified 
crystallographically (Christopher et al., 2015). It is important to 
note that, while this kind of structure-guided drug discovery 
and optimization is relatively routine for other drug targets, where 
several leading compounds are serially crystallized with the mo-
lecular target and derivatives synthesized based on insights 
gained from the structures, routine crystallization of GPCRs re-
mains highly challenging.
Structure-Based Virtual Discovery of Novel Chemotypes 
for GPCRs
The availability of GPCR structures has inspired a large number 
of successful computational campaigns aimed at discovering 
novel chemical probes with unique chemical structures (e.g., 
chemotypes) for GPCRs (e.g., virtual screening). One of the 
earliest successes was automated molecular docking to b2ARthat yielded nanomolar potency inverse agonists (Kolb et al.,
2009). One of the resulting compounds, when crystallized,
revealed a novel b2AR ligand-binding conformation (Wacker
et al., 2010).
Given this and other successes in structure-guided discovery
of new GPCR ligands, one might ask whether it might be
possible to use molecular models in lieu of experimentally deter-
mined structures as templates for docking in other receptors. An
early example of this approach with the D3 dopamine receptor
(Carlsson et al., 2011) featured 3.3 million compounds docked
initially against a homology model of the D3 dopamine receptor
that used b2AR as a template. Several nanomolar potency antag-
onists were discovered. Docking was also performed using the
D3 receptor X-ray structure as a template (Chien et al., 2010)
and, surprisingly, a distinct set of nanomolar potency antago-
nists was identified. What emerged from this exercise was the
observation that the slightly different conformations sampled
by the crystal structure and the models of this receptor yielded
chemically distinct sets of active molecules.
An exciting extension of this overall approach—and one which
may prove to provide a template going forward—is the serial
structure-guided and docking-based optimization of active mol-
ecules into potential therapeutic entities. In one instance, three
million commercially available compounds from the ZINC data-
base (Irwin and Shoichet, 2005) were docked against an inactive
conformation of the m opioid receptor (Manglik et al., 2016), the
molecular receptor for morphine. Initial lead compounds from
the docking campaign were experimentally tested, and commer-
cially available analogs were purchased to obtain ligands of
higher affinity. Active compounds were then optimized through
modest medicinal chemistry, guided by their docking pose,
structural considerations, and experimental pharmacology.
This process ultimately yielded PZM-21, a selective, high-affinity
m opioid agonist with modest G protein bias that was ultimately
found to be analgesic with fewer side effects compared to
morphine (Manglik et al., 2016).
Structure-Inspired Discovery of Chemical Probes for
oGPCRs
That homology models can be used to identify novel chemical
matter using virtual ligand screening has proven to be particu-
larly useful for oGPCRs, for which conventional ligand screening
campaigns have not yielded useful probes. For instance, selec-
tive allosteric modulators (both NAMs and PAMs) were identified
for the oGPCRs GPR68 and GPR65 and further optimized by a
combination of physical screening and in silico docking (Huang
et al., 2015b). One GPR68 PAM, ogerin, was demonstrated
to have on-target activity in vivo by modulating conditioned
fear responses in mice. A similar approach has recently been
used to identify small-molecule ligands for the oGPCRs
GPR171 (Wardman et al., 2016) and MRGPRX2 (Lansu et al.,
2017), and these compounds were subsequently used to further
characterize the receptor’s role in feeding behavior and itch,
respectively.
The successful use of homology models, however, largely de-
pends on the accuracy of the models. The analysis of docking
results is a process that considers previous biochemical and
pharmacological information regarding ligand-receptor interac-
tions as validated from crystal structures. Accordingly, the
Figure 5. Computational Approaches
Generate Novel Tool Compounds for GPCRs
As shown here, the ‘‘pickpocketing’’ approach
identifies GPCRs with potentially related ligand-
binding properties according to ligand contact
strength informed pocket alignment. Similar
ligand-binding properties between the Neuropep-
tide S receptor (NPS) and the orphan GPCR
GPR37L1 identified the NPS receptor ligand
SHA68 as a novel ligand to interrogate GPR37L1
function. Data schematized according to Ngo
et al. (2017).description of key residues accessible for ligand binding in class
A GPCRs (Gloriam et al., 2009) or the definition of so-called pro-
tein-ligand interaction fingerprints (reviewed in Vass et al. [2016])
not only greatly enhances the identification of relevant mole-
cules, but also highlights the importance of using tool com-
pounds to study GPCRs interactions and function.
An alternative approach, dubbed ‘‘pickpocketing,’’ analyzes
ligand-residue contact strength to identify potential ligand-bind-
ing similarity between non-homologous receptors. This method
allowed the authors of a recent paper to identify new chemo-
types for the oGPCR GPR37L by ‘‘stealing’’ ligands from
orexin and neuropeptide receptors that possess sufficient
chemical matter and exhibit substantial contact-strength similar-
ity with GPR37L (Ngo et al., 2017) (Figure 5). Taken together,
these recent successes indicate that homology-model-based
approaches can be powerful and useful approaches for
discovering agonists, antagonists, and allosteric modulators of
oGPCRs.
Conclusions and Future Directions
As is clear, the past 10 years have witnessed a renaissance in
GPCR research catalyzed by structural insights into the most
basic aspects of GPCR ligand binding and signaling. Concepts
of ligand recognition previously considered to be theoretical—
such as allosteric modulation (Kenakin and Boselli, 1989)—are
now firmly validated from structural and functional perspectives.
Additionally, we are beginning to get hints of how different
ligands might stabilize distinct conformational ensembles, lead-
ing to a variety of active, inactive, and biased states as was pre-
dicted many years ago (Urban et al., 2007). Finally, the plethoraof structures has provided computational
biologists with tremendous opportunities
for both structure-guided and -inspired
drug discovery.
Although these advances are breath-
taking when considered from a historical
perspective, huge gaps remain in our un-
derstanding of GPCR structure, function,
signaling, and pharmacology. Clearly,
our understanding of GPCR functional
selectivity from a mechanistic, molecular
perspective is inadequate and remains
phenomenological. Thus, for instance,
there are no structures of GPCRs with
G proteins in complex with G-protein-biased agonists, nor are there structures of GPCRs with ar-
restin-biased ligands in complex with arrestin.
Additionally, how biased ligands might stabilize distinct states
is unknown, and approaches to discover and develop such li-
gands is discovery based rather than mechanistically based.
Consider, for instance, that although the structures of more
than 40 GPCRs have been solved by X-ray crystallography, in
most cases, this has been achieved with only one ligand and
only in an inactive state. For some receptors, including b2AR
and A2AAR, multiple ligand complexes are available, but only
minimal plasticity within the binding pocket is evident. In our
recent studies on 5-HT2B receptors, however, we observed
extensive plasticity within the binding pocket of a GPCR when
examining structures stabilized by similar compounds (Wacker
et al., 2017). From the foregoing, we predict that depending
upon the particular GPCR and ligands that are examined, a range
of conformational rearrangements within the binding site will be
observed. Further, it is clear that regions of GPCRs normally
considered to be ‘‘undruggable’’ (e.g., intracellular loops, inter-
faces, etc.) (Oswald et al., 2016) are sites of action for current
and potential therapeutics. Thus, understanding and predicting
howGPCR binding sites change in complex with specific ligands
and how these alterations ultimately lead to differential signaling
and physiological outcomes remain major grand challenges for
structural biologists and molecular pharmacologists.
Finally, although GPCRs continue to be the most popular fam-
ily of molecular targets for therapeutic drug discovery, current
medications target a vanishingly small number of GPCRs.
Although drugs are in development targeting 100 GPCRs,
huge gaps remain regarding our understanding of oGPCRs
and how they might be useful as therapeutic targets. As was 
recently emphasized, for more than half of the druggable GPCRs 
in the human genome, little useful information is available 
regarding their roles in normal physiology, much less their utility 
as therapeutic targets (Roth and Kroeze, 2015). Additionally, 
many GPCRs remain ‘‘orphan’’ by having no bona fide endoge-
nous agonists identified (Roth and Kroeze, 2015). While classical 
knockout studies and/or chemo- and optogenetic approaches 
may provide some insight into oGPCR function, it is tool com-
pounds that are desperately required to delineate their physio-
logical roles, characterize their function on a molecular level, 
and perhaps thereby identify novel therapeutic targets. Applica-
tion of technologies such as virtual ligand screening and a variety 
of computational approaches to build ligands de novo, both 
enabled by molecular GPCR studies, are already beginning to 
yield valuable chemical tools. With the implementation of 
machine learning technology to better predict compound activity 
in a complex biological system, the speed and success rate of 
computational screening is more than likely to drastically in-
crease over the coming years. Based on an ever-increasing 
number of GPCR structures, computational approaches are 
thus poised to augment or even replace manual high-throughput 
drug screening while accelerating the generation of new tool 
compounds to study GPCR function or develop drug design 
platforms. Ligands, synthetic or natural, are the single most 
powerful tool for elucidating GPCR mechanisms and physi-
ology—data that will not only help to better understand the single 
largest class of membrane proteins, but likely also translate into 
better therapies.
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Morello, J.P., Salahpour, A., Laperriè re, A., Bernier, V., Arthus, M.F., Lonergan, 
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